This site is only for UK healthcare professionals and contains promotional information.

Prescribing Information can be found at the bottom of this page.

Explore the benefits

ILUMETRI® delivers sustained efficacy for nearly 5 years1

Adapted from Thaçi D, et al. 2021.

Multiple imputation data.

ILUMETRI® also demonstrates effectiveness in real-life clinical practice2

‘Efficacy assessments show an improvement from baseline comparable to the reSURFACE data’2
Close to 9 out of 10 patients achieved psoriasis control (PASI ≤3) at Week 282
79% numerical improvement in QoL at Week 282
No clinically relevant safety issues observed2
Positive impact on QoL (DLQI) in a real-world setting2

Baseline DLQI: 12.0 (±5.6)

ILUMETRI® has also demonstrated high levels of PASI response in real-world clinical practice3

Proportion of patients with PASI 90 and PASI 100 responses by week

Adapted from Burlando M, et al. 2021.

Real-world study of 26 patients with moderate-to-severe plaque psoriasis. Patients assessed at baseline and Weeks 4, 12 and 24 by clinical visit and PASI, PGA and DLQI scores.

Improved quality of life4,5

64% of patients reported that psoriasis no longer affected their lives at W28

A consistent safety profile1,6

Low rates of respiratory infections

Convenient, flexible dosing5

Just 4 doses per year during maintenance

Cost effective for the NHS7

When response is assessed at W28
Response rates maintained despite metabolic syndrome8
decrease in PASI from baseline (reSURFACE 2 ILUMETRI® 100 mg, with MetS)
Itch reduction in real-world practice9
numerical reduction in VAS itch score
(OC data, n=122)
Improvement in head and neck areas10

of patients achieved complete head and neck clearance by W12

You might also be interested in

Meet Georgia, a patient suffering with itch
Find out more about the benefits of ILUMETRI® for patients suffering with itch
Meet Marc, a patient with metabolic syndrome
Find out more about the benefits of ILUMETRI® for patients with metabolic syndrome

DLQI, Dermatology Life Quality Index. OC, observed case. PASI, Psoriasis Area Severity Index. PGA, Physician Global Assessment. QoL, quality of life.

  1. Thaçi D, et al. Br J Dermatol 2021. DOI: 10.1111/bjd.19866.
  2. Drerup K, et al. Real world data from a large prospective cohort study (KTC) using tildrakizumab in psoriasis. EADV Congress. 29–31 October 2020. Poster: P1294.
  3. Burlando M, et al. Drugs Context 2021;10:2–6.
  4. Reich K, et al. Lancet 2017;390:276–288.
  5. ILUMETRI® Summary of Product Characteristics. Almirall.
  6. Reich K, et al. Br J Dermatol 2020;182:605–617.
  7. NICE. Tildrakizumab for treating moderate to severe plaque psoriasis. Available at:
  8. Lebwohl MG, et al. J Am Acad Dermatol 2021;84:398–407.
  9. Tsianakas A, et al. Interim analysis of the non-interventional study TILOT: effectiveness of tildrakizumab in long-term treatment of moderate to severe plaque psoriasis in routine practice. EADV Congress. 29–31 October 2020. Poster: P1336.
  10. Menter MA, et al. J Eur Acad Dermatol Venereol 2020;34:e803–e805.

UK-ILU-2100104 November 2021

My Favorites